$PSEC

Barry John F purchased $2.4M of PSEC

Barry John F (CHIEF EXECUTIVE OFFICER) purchased 1,067,648 shares of PROSPECT CAPITAL CORP (PSEC) at an average of $2.27 ($2.27–$2.27, $2.43M total) across 2 trades on 2026-06-23.

Original reporting
SEC EDGAR · Barry John F
Published Jun 25, 2026, 8:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PSEC
Bullish
medium confidence
Mentioned
$PSEC
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSECBullishLow
01

Why it matters

The newest concrete fact is the CEO’s open-market purchase of ~$2.43M worth of PSEC shares at about $2.27 per share.

02

Market read

Traders may treat the disclosure as a small positive sentiment input, but it does not introduce new operating or financial information.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article still lacks context on prior holdings, motivations, and whether the buy is part of a broader pattern.

Relevance 7/10Novelty 5/10Timing: filed after-hours on 2026-06-25; trade date 2026-06-23

Background

The article is an SEC Form 4 insider transaction disclosure for Prospect Capital Corp (PSEC).

Company-level read

Ticker impact

$PSECBullishMedium confidence
Context

SEC Form 4 shows CEO Barry John F bought 1,067,648 shares of Prospect Capital at ~$2.27 on 2026-06-23.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides no new company fundamentals (earnings, guidance, deals) beyond the transaction details.

Market effects

Minimal; this is a single-company insider transaction with no sector-wide regulatory or macro trigger.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (tax planning, diversification, or pre-planned behavior) and may not reflect a change in near-term fundamentals.

Key entities

  • Prospect Capital Corp

    Subject of the Form 4 insider transaction; CEO Barry John F purchased shares on 2026-06-23.

  • Barry John F

    Chief Executive Officer (and officer/director/10% owner) who reported the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PSECMed

Prospect Capital Corp (PSEC) (Q4 2026) Earnings Call Highlights: Consistent NII

Prospect Capital Corp (PSEC) reported Q4 2026 results with flat net investment income at $78M, NAV at $5.71/share, and a 28.6% net debt-to-assets ratio. The company highlighted a successful exit of Valley Electric, AI initiatives, and middle-market lending performance. Real estate exposure is 14% of investments, and liquidity remains strong with $1.6B in cash and undrawn revolver commitments.

$PSECHigh

PROSPECT CAPITAL CORP (PSEC): Results of Operations and Financial Condition

PROSPECT CAPITAL CORP (PSEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prospect Capital Announces June 2026 Results NEW YORK, August 20, 2026 (GLOBE NEWSWIRE) – Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter and fiscal year ended June 30, 2026. FINANCIAL

$PSECMed

Palmer Square Capital BDC Inc. Q2 2026 Earnings Call Summary

Palmer Square Capital BDC Inc. reported Q2 2026 results, citing disciplined capital allocation and a subdued M&A backdrop. NAV per share fell to $13.21 on BSL fair value moves; nonaccrual rate was 0.29%. Management expects a BDC CLO reset to be accretive from Q4 2026 and set a Q3 base dividend of $0.36 plus potential supplements. It expanded a $30m share repurchase program.